Table 1.
Demographics and clinical characteristics of IBD patients.
| Remission (n = 38) |
Mild (n = 45) |
Moderate–Severe (n = 20) |
Total (n = 103) |
p-Value | |
|---|---|---|---|---|---|
| Age, years | 42.0 ± 12.5 | 40.3 ± 12.5 | 37.3 ± 11.0 | 40.3 ± 1.2 | 0.39 |
| Gender, women | 19 (50.0%) | 25 (55.6%) | 7 (35.0%) | 51 (49.5%) | 0.31 |
| BMI, kg/m2 | 23.96 ± 3.96 | 24.59 ± 5.28 | 24.56 ± 4.39 | 24.35 ± 0.46 | 0.81 |
| Type of disease | 0.86 | ||||
| UC | 15 (39.5%) | 17 (37.8%) | 9 (45.0%) | 41 (39.8%) | |
| CD | 23 (60.5%) | 28 (62.2%) | 11 (55.0%) | 62 (60.2%) | |
| Duration of disease, years | 18.4 ± 9.9 | 12.9 ± 7.9 a | 9.7 ± 7.8 a | 14.3 ± 0.9 | <0.001 ** |
| CRP, mg/L | 2.38 ± 3.43 | 4.76 ± 6.90 | 6.97 ± 14.31 | 4.30 ± 0.80 | 0.11 |
| Blood leucocytes count, GPt/L | 6.69 ± 1.94 | 7.08 ± 2.05 | 8.10 ± 2.56 | 7.14 ± 0.21 | 0.06 |
| Fecal Calprotectin, µg/g | 39 ± 30 | 1017 ± 1617 | 1538 ± 3324 | 870 ± 231 | 0.06 |
| ADS-L depression score | 15.71 ± 4.72 | 15.09 ± 4.43 | 12.05 ± 5.31 a, b | 14.73 ± 0.48 | 0.018 * |
| TNF-inhibitor use, n | 16 (42.1%) | 27 (60.0%) | 7 (35.0%) | 50 (48.5%) | 0.10 |
Results are expressed as mean ± SD or n (%). a Significantly different with respect to remission IBD. b Significantly different with respect to mild IBD. * p < 0.05; ** p < 0.01.